Ascentage Pharma Group International (HK:6855)
:6855
Top Page
Ascentage Pharma Group International
(6855)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$45.00
▼(-11.59% Downside)
Action:ReiteratedDate:01/08/26
The score is held down primarily by weak financial quality despite rapid revenue growth—losses, negative free cash flow, and high leverage are key risks. Technicals are also soft with the stock below longer-term moving averages and negative MACD, while valuation provides limited support because the company is not profitable and no dividend yield is available.
Positive Factors
Strong revenue growth
A 342% year-over-year revenue increase reflects durable commercial or clinical uptake of programs and expanding operational scale. Sustained top-line growth can support higher future R&D investment, improve negotiating leverage with partners, and reduce reliance on external financing as programs progress.
Negative Factors
Ongoing net losses
Persistent negative EBIT and net margins limit internal funding capacity and prolong the need for external capital. Continued losses weigh on return metrics and increase sensitivity to financing conditions, potentially forcing program cutbacks or dilutive raises that affect long-term strategy execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
A 342% year-over-year revenue increase reflects durable commercial or clinical uptake of programs and expanding operational scale. Sustained top-line growth can support higher future R&D investment, improve negotiating leverage with partners, and reduce reliance on external financing as programs progress.
Read all positive factors
Ascentage Pharma Group International (6855) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$19.28B
Dividend YieldN/A
Average Volume (3M)2.29M
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth-56.94%
EPS Growth-190.36%
CountryHK
Employees567
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.04
Shares Outstanding373,322,200
10 Day Avg. Volume1,948,642
30 Day Avg. Volume2,293,783
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)48.81
Price to Sales (P/S)13.15
P/FCF Ratio-95.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.98
Revenue Forecast (FY)HK$802.97M
Ascentage Pharma Group International Business Overview & Revenue Model
Company Description
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP13...
How the Company Makes Money
Ascentage Pharma generates revenue through multiple streams, primarily from the development and commercialization of its pharmaceutical products. The company earns money by advancing its drug candidates through clinical trials, ultimately seeking ...
Ascentage Pharma Group International Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
40
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 390.60M | 980.65M | 221.98M | 209.71M | 27.91M | 12.45M |
| Gross Profit | 354.93M | 951.57M | 191.44M | 187.71M | 24.58M | 10.48M |
| EBITDA | -1.04B | -299.63M | -743.61M | -835.99M | -915.99M | -641.77M |
| Net Income | -1.16B | -405.43M | -925.64M | -882.92M | -782.42M | -677.61M |
Balance Sheet | ||||||
| Total Assets | 3.05B | 2.62B | 2.50B | 2.83B | 2.94B | 1.73B |
| Cash, Cash Equivalents and Short-Term Investments | 1.66B | 1.26B | 1.10B | 1.50B | 1.75B | 1.03B |
| Total Debt | 1.72B | 1.67B | 1.80B | 1.79B | 1.08B | 529.70M |
| Total Liabilities | 2.37B | 2.34B | 2.43B | 2.42B | 1.71B | 884.42M |
| Stockholders Equity | 666.00M | 264.19M | 60.42M | 408.66M | 1.23B | 846.62M |
Cash Flow | ||||||
| Free Cash Flow | -216.89M | -135.65M | -782.92M | -857.20M | -1.04B | -859.88M |
| Operating Cash Flow | -189.09M | -111.36M | -726.08M | -653.91M | -604.68M | -609.96M |
| Investing Cash Flow | -935.28M | -362.04M | 21.92M | -384.61M | -466.52M | -107.37M |
| Financing Cash Flow | 868.61M | 314.77M | 368.75M | 619.27M | 1.78B | 1.04B |
Ascentage Pharma Group International Technical Analysis
Neutral
50.90
Price Trends
46.84
Positive
52.76
Negative
64.52
Negative
Market Momentum
0.50
Negative
63.78
Neutral
87.17
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6855, the sentiment is Neutral. The current price of 50.9 is above the 20-day moving average (MA) of 45.93, above the 50-day MA of 46.84, and below the 200-day MA of 64.52, indicating a neutral trend. The MACD of 0.50 indicates Negative momentum. The RSI at 63.78 is Neutral, neither overbought nor oversold. The STOCH value of 87.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6855.
Ascentage Pharma Group International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$23.20B | 31.11 | -3.42% | ― | 58.24% | 38.85% | |
66 Neutral | HK$27.73B | 34.57 | 25.67% | ― | 2.57% | 18.79% | |
53 Neutral | HK$14.43B | -38.53 | -11.43% | ― | 102.73% | 38.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$40.58B | -22.62 | -14.53% | ― | 38.56% | 48.26% | |
44 Neutral | HK$19.28B | -6.78 | -123.74% | ― | -56.94% | -190.36% |
* Healthcare Sector Average
HK:6855
Ascentage Pharma Group International
52.05
18.40
54.68%
HK:9969
InnoCare Pharma Ltd.
15.52
7.86
102.61%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.38
13.70
108.04%
HK:1952
Everest Medicines Ltd.
40.80
-4.30
-9.53%
HK:2096
Simcere Pharmaceutical Group Limited
13.62
6.44
89.69%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
76.60
49.85
186.36%
Ascentage Pharma Group International Corporate Events
Ascentage Pharma Enhances Board Structure, Sets Shareholder Vote on Equity Grant
Dec 30, 2025
Ascentage Pharma Group International has strengthened its corporate governance and RD oversight by revising the composition of its nomination committee, appointing Dr. Debra Yu as an additional member, and naming existing independent non-executive...
Ascentage Pharma Sets Out Board Line-Up and Key Committee Roles
Dec 30, 2025
Ascentage Pharma Group International has announced the current composition of its board of directors, led by Executive Director and Chairman Dr. Yang Dajun and supported by a mix of non-executive and independent non-executive directors with scient...
Ascentage Pharma’s Olverembatinib Phase III Trial Cleared by US FDA and EMA
Dec 5, 2025
Ascentage Pharma has announced the clearance from the US FDA and EMA for a global Phase III study of olverembatinib in combination with chemotherapy for newly diagnosed Ph+ ALL patients. This study, known as POLARIS-1, aims to accelerate the drug&...
Ascentage Pharma Grants Further RSU Awards to Strengthen Growth Strategy
Nov 27, 2025
Ascentage Pharma Group International announced the further grant of awards under its 2022 RSU Scheme, allocating 1,304,457 RSUs to 146 selected individuals, including directors and service providers. This move is part of the company’s strate...
Ascentage Pharma to Showcase Latest Clinical Study Results at ASH 2025
Nov 4, 2025
Ascentage Pharma announced that it will present the latest results from multiple clinical studies of its investigational drug candidates at the 67th American Society of Hematology (ASH) Annual Meeting in 2025. The presentations will include data o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.